newsfilter
← Latest News
GlobeNewswire·

SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases

Intravenous SCY-247 was generally well tolerated in healthy participants, with no drug-related serious adverse eventsOnce-daily intravenous doses of 50 mg or higher achieved exposures at or above the target identified